{"id":"bupropion-and-transdermal-patch","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Dry mouth"},{"rate":"10-20%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1201735","moleculeType":"Small molecule","molecularWeight":"320.66"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action is thought to contribute to its antidepressant and smoking cessation effects. The transdermal patch formulation allows for a more consistent release of the drug into the bloodstream.","oneSentence":"Bupropion is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:28.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Smoking cessation"}]},"trialDetails":[{"nctId":"NCT04634071","phase":"PHASE2","title":"Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment","status":"COMPLETED","sponsor":"Joseph Valentino, MD","startDate":"2021-01-12","conditions":"Smoking Cessation, Cancer, Treatment-Related","enrollment":126},{"nctId":"NCT04717544","phase":"NA","title":"Embedding Comprehensive Smoking Cessation Programs Into Community Clinics","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2019-10-01","conditions":"Smoking Cessation","enrollment":406},{"nctId":"NCT02050308","phase":"PHASE3","title":"Web-based Smoking Cessation Program for Tribal College Students","status":"COMPLETED","sponsor":"Won Choi, PhD, MPH","startDate":"2015-05","conditions":"Smoking Cessation","enrollment":251},{"nctId":"NCT02995915","phase":"PHASE4","title":"Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Smoking Cessation, Alcohol Drinking","enrollment":45},{"nctId":"NCT02869451","phase":"NA","title":"Mobile Contingency Management for Marijuana and Tobacco Cessation","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-08","conditions":"Cigarette Smoking, Marijuana Abuse","enrollment":7},{"nctId":"NCT00086411","phase":"PHASE2","title":"Comparing Smoking Treatment Programs for Lighter Smokers - 1","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2003-09","conditions":"Tobacco Use Disorder","enrollment":260},{"nctId":"NCT01592695","phase":"PHASE2","title":"Tailored Tobacco Quitline for Rural Veterans","status":"COMPLETED","sponsor":"Iowa City Veterans Affairs Medical Center","startDate":"2012-06","conditions":"Cigarette Smoking","enrollment":63},{"nctId":"NCT02994082","phase":"NA","title":"Treating Smokeless Tobacco Use in Rural Veterans","status":"UNKNOWN","sponsor":"Mark Vander Weg","startDate":"2016-12","conditions":"Smokeless Tobacco, Nicotine Dependence","enrollment":123},{"nctId":"NCT02420015","phase":"PHASE4","title":"Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-03-27","conditions":"Schizophrenia, Cigarette Smoking","enrollment":35},{"nctId":"NCT02873754","phase":"NA","title":"Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-01","conditions":"Smoking","enrollment":11},{"nctId":"NCT01892813","phase":"PHASE3","title":"Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers","status":"UNKNOWN","sponsor":"Mark Vander Weg","startDate":"2013-07","conditions":"Nicotine Dependence, Tobacco Use","enrollment":411},{"nctId":"NCT00218218","phase":"PHASE2","title":"Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2002-06","conditions":"Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia","enrollment":48},{"nctId":"NCT00132821","phase":"PHASE4","title":"Impact of Smoking Cessation on Sleep - 5","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2005-08","conditions":"Tobacco Use Cessation, Sleep Disorders","enrollment":59},{"nctId":"NCT01456936","phase":"PHASE4","title":"Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Smoking Cessation","enrollment":8144},{"nctId":"NCT00296647","phase":"PHASE4","title":"Smoking Cessation Intervention: Effectiveness in Primary Care","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-09","conditions":"Tobacco Dependence","enrollment":1346},{"nctId":"NCT01990079","phase":"NA","title":"Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-12","conditions":"PTSD, Smoking","enrollment":15},{"nctId":"NCT01850589","phase":"NA","title":"Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2011-03","conditions":"Smoking Cessation","enrollment":44},{"nctId":"NCT00625131","phase":"EARLY_PHASE1","title":"Nicotine Patch Pretreatment for Smoking Cessation in PTSD","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2008-05","conditions":"Stress Disorders, Posttraumatic, Tobacco Use Disorder","enrollment":87},{"nctId":"NCT00125905","phase":"NA","title":"ISTAPS: A Stepped Primary Care Smoking Cessation Intervention","status":"UNKNOWN","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2003-10","conditions":"Smoking Cessation","enrollment":3012},{"nctId":"NCT00108537","phase":"PHASE3","title":"Non-Nicotine Agents for Smoking Cessation","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2003-10","conditions":"Tobacco Use Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bupropion and transdermal patch","genericName":"bupropion and transdermal patch","companyName":"US Department of Veterans Affairs","companyId":"us-department-of-veterans-affairs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain. Used for Major depressive disorder, Smoking cessation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}